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Out-of-Sequence Signal 3 as a Mechanism for Virus-
Induced Immune Suppression of CD8 T Cell Responses
Stina L. Urban, Raymond M. Welsh*
Department of Pathology, Immunology and Virology Program, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
Abstract
Virus infections are known to induce a transient state of immune suppression often associated with an inhibition of T cell
proliferation in response to mitogen or cognate-antigen stimulation. Recently, virus-induced immune suppression has been
linked to responses to type 1 interferon (IFN), a signal 3 cytokine that normally can augment the proliferation and
differentiation of T cells exposed to antigen (signal 1) and co-stimulation (signal 2). However, pre-exposure of CD8 T cells to
IFN-inducers such as viruses or poly(I:C) prior to antigen signaling is inhibitory, indicating that the timing of IFN exposure is
of essence. We show here that CD8 T cells pretreated with poly(I:C) down-regulated the IFN receptor, up-regulated
suppressor of cytokine signaling 1 (SOCS1), and were refractory to IFNb-induced signal transducers and activators of
transcription (STAT) phosphorylation. When exposed to a viral infection, these CD8 T cells behaved more like 2-signal than
3-signal T cells, showing defects in short lived effector cell differentiation, reduced effector function, delayed cell division,
and reduced levels of survival proteins. This suggests that IFN-pretreated CD8 T cells are unable to receive the positive
effects that type 1 IFN provides as a signal 3 cytokine when delivered later in the signaling process. This desensitization
mechanism may partially explain why vaccines function poorly in virus-infected individuals.
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Introduction
The fact that virus infections can induce a transient state of
immune suppression was first described over a century ago, as
patients acutely infected with the measles virus failed to develop a
recall response to tuberculin even though they had previously been
immunized [1]. Since then, infection with a number of other
viruses, including HIV [2], Lymphocytic choriomeningitis virus
(LCMV) [3], CMV [4] and Influenza A [5] have been shown to
induce a transient state of immune suppression in humans and
animal models [6,7]. Although virus-induced immune suppression
can affect many aspects of the immune system, it is often
associated with a reduced ability of T cells to proliferate in
response to mitogens or antigen-specific stimulation. Viruses may
induce this suppression by directly infecting cells of the immune
system, but they can also induce immune suppression without
directly targeting hematopoietic cells. In vitro studies have shown
that inhibition of T cell proliferation can be due to death receptor-
associated activation-induced cell death (AICD) [8,9], impaired
antigen presentation [10,11], exposure to immunosuppressive
cytokines [12], and perhaps to competition for limited amounts of
cytokine growth factors. Recent in vivo studies from our
laboratory showed that type 1 IFN can be a profound and
universal factor inducing suppression of T cell proliferation during
viral infections if the T cells are exposed to type 1 IFN prior to
encountering their cognate ligand [13].
Efficient clonal expansion and differentiation of CD8 T cells is
required to develop protective memory CD8 T cells. This requires
three signals: a cognate peptide MHC-TCR interaction (signal 1),
co-stimulation (signal 2), and infection-induced cytokines (signal 3)
[14–16]. CD8 T cells that encounter antigen and co-simulation
undergo programmed cell division, but these two signals alone are
not sufficient for full effector cell differentiation and survival into
memory [14,17,18]. CD8 T cells need a third signal, provided by
cytokines, including IL-12 or type 1 IFN, for efficient clonal
expansion, differentiation into various effector populations,
acquisition of cytolytic effector functions, and memory formation
[15,19]. One in vitro study showed that without IL-12, CD8 T
cells did not proliferate well or develop full effector function [20].
Type 1 IFN, however, can evidently substitute for IL-12 as a signal
3 cytokine [21,22].
Signal 3 cytokines are required for efficient clonal expansion in
response to antigen, and the infecting pathogen and resulting
inflammatory environment determine which cytokine(s) provide
signal 3 activity [23–26]. LCMV-specific CD8 T cells use type 1
IFN as the signal 3 cytokine for effective primary T cell expansion
[25,27,28], whereas Listeria and VSV depend on both type 1 IFN
and IL-12 [23,25,29,30]. Studies showed that IFNab Receptor (R)
KO LCMV-specific transgenic P14 CD8 T cells divided similarly
to WT P14 cells but had reduced survival, thereby limiting their
overall clonal expansion [27]. In other systems, the addition of
adjuvants or IL-12 to activated CD8 T cells promoted their
expansion by up-regulating the IkB family member BCL3, which
was found to prolong T cell survival [31–33].
Signal 3 cytokines also play an important role in CD8 T cell
differentiation into various phenotypic and functional effector
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populations. Differences in CD8 T cell exposure to co-stimulatory
molecules and cytokines can alter their differentiation into early
effector cells (EECs), short-lived effector cells (SLECs) and
memory precursor effector cells (MPECs) [17,25,34]. Recent
studies investigating the role for signal 3 cytokines in primary CD8
T cell responses have shown that loss of IL-12R, IFNAR, or both
receptors can alter CD8 T cell differentiation, showing reduced
SLEC and increased MPEC formation [25,35]. Signal 3 cytokines
have also been shown to augment the acquisition of CD8 T cell
effector functions, including production of cytokines (IFNc and
TNF) and CTL activity. In vitro studies showed that without type
1 IFN or IL-12, CD8 T cells had decreased lytic ability and low
levels of granzyme B expression [21,27,36]. Additional in vivo
studies showed reduced granzyme B expression in IFNabR KO
transgenic P14 CD8 T cells compared to WT P14 CD8 T cells
[27]. However, not all infection models show the same require-
ments for the specific signal 3 cytokines in driving these effector
functions [25,27].
Type 1 IFN signaling is complex in that it can activate multiple
downstream pathways, including the JAK/STAT pathway.
Engagement of the type 1 IFN receptor promotes phosphorylation
of downstream STAT molecules, including STAT1, 3, 4, and 5
[37]. The combination of STAT molecule(s) that are phosphor-
ylated and translocated into the nucleus controls the outcome of
CD8 T cell activation. Activation of STAT1 downstream of type 1
IFN receptor signaling generally has anti-proliferative effects on
CD8 T cells [38,39]. In contrast, type 1 IFN-mediated activation
of STAT3 and/or STAT5 has anti-apoptotic and pro-mitogenic
effects [38,40,41]. Type 1 IFN signaling via STAT4 promotes
both the acquisition of effector function, including IFNc produc-
tion, and clonal expansion [21,42]. Recent studies showed that
during LCMV infection, virus-specific CD8 T cells had decreased
total STAT1 levels and increased STAT4 levels, thereby
promoting effector T cell differentiation and clonal expansion
over anti-proliferative effects [38,43]. Thus, type 1 IFN can have
both inhibitory and stimulatory effects on CD8 T cell prolifera-
tion, and when type 1 IFN provides signal 3 cytokine activity, it
has positive effects on CD8 T cell expansion.
The timing of exposure of CD8 T cells to all 3 signals is very
important, as T cells exposed to virus-induced inflammatory
environments prior to cognate antigen respond differently to
signals 1 and 2 compared to CD8 T cells from naı¨ve environments
[13,44,45]. Under circumstances when CD8 T cells see antigen
and co-stimulation prior to or at the same time as inflammatory
cytokines, IL-12 or type 1 IFN have positive effects on T cell
differentiation and expansion. However, CD8 T cells pre-exposed
to virus-induced inflammatory environments showed reduced
proliferation when exposed to cognate antigen [13,44]. Virus-
induced impaired proliferation could be mimicked by the type 1
IFN-inducer poly(I:C). In this study, we utilized poly(I:C) to study
the mechanism of IFN-mediated virus-induced T cell immune
suppression. We sought to investigate whether the IFN-mediated
suppression of CD8 T cells is due to type 1 IFN having direct
suppressive effects on CD8 T cells or if it inhibits the positive
effects IFN has on CD8 T cells. We show here that poly(I:C)-
pretreated CD8 T cells are refractory to IFNb signaling in terms of
downstream STAT phosphorylation, suggesting that they are
unable to receive positive effects that signal 3 cytokines normally
provide during acute infections. Indeed, these out-of-sequence
signal 3 CD8 T cells were found to behave more similar to 2-
signal-only CD8 T cells rather than T cells that receive all 3 signals
in the proper order. Therefore, the inability to respond to signal 3
cytokines limits CD8 T cell expansion and suggests a causative
mechanism for reduced vaccine efficacy when administered during
acute infections.
Results
Poly(I:C)-induced sensitization to impaired proliferation is
transient and requires direct effects of type 1 IFN
Previously, we had shown that CD8 T cells exposed to
exogenous cognate antigen 3–9 days, but not 12 days, after
initiation of a virus infection proliferated poorly in response to a
cognate antigen stimulus, and viruses that induced a strong type 1
IFN response had the greatest suppressive effects [13]. To
investigate the mechanism of this virus-induced suppression of T
cell proliferation, the IFN-inducer poly(I:C) was used to prime
CD8 T cells. Congenic transgenic LCMV-specific P14 CD8 T
cells were used here to study virus-specific T cells exposed to the
IFN-inducer poly(I:C) prior to infection. As demonstrated in
Figure 1A, Ly5.1 P14 cells were transferred into Ly5.2 B6 hosts
that were inoculated with either HBSS or poly(I:C). One to three
days later, splenocytes were isolated, and equal numbers of P14
cells (enumerated by flow cytometry staining) were transferred into
recipients that were immediately infected with LCMV. Spleens
from recipient mice were harvested at the peak of transgenic T cell
expansion, day 7 post infection, and the proportion (Figure 1B
and 1C) and total number (Figure 1D) of transgenic P14 cells
were then determined. Suppression of proliferation of poly(I:C)-
pretreated P14 cells (black bars) was greatest at 1 and 2 days of
treatment compared to control treated cells (open bars). After 3
days of pre-treatment, clonal expansion of poly(I:C)-pretreated
P14 cells was comparable to that of the HBSS-pretreated control
P14 cells, indicating that poly(I:C)-mediated suppression of
proliferation is a transient effect.
Because type 1 IFN is required for efficient clonal expansion of
LCMV-specific CD8 T cells, we investigated its role in the
reduced proliferation seen in poly(I:C)-pretreated CD8 T cells. We
previously showed that impaired proliferation required direct
effects of type 1 IFN acting on the T cell [13], and this is illustrated
in Figure 1E, using a similar experimental set up as that
described in Figure 1A. Congenic Thy1.1 IFNabR KO P14
CD8 T cells were transferred into Thy1.2 mice that were
inoculated with either HBSS or poly(I:C). One day later, equal
numbers of transgenic T cells were transferred into mice prior to
Author Summary
Vaccines are used to protect individuals against infection
with a number of different pathogens and depend on the
formation of antigen specific memory cells. The efficacy of
vaccines can be affected by a number of different factors.
It has been known for some time now that suppression of
the immune system occurs during acute viral infections.
Thus, receiving a vaccine during an acute illness may
reduce the efficacy of the vaccine administered. We have
identified a common mechanism of immune suppression
that may occur with many different pathogens that induce
a particular inflammatory response. Any pathogen that
induces type 1 interferon could potentially suppress the
immune response to a subsequent pathological insult. The
mechanism of immune suppression identified here was
not having a direct negative effect on lymphocytes, but
rather was inhibiting the cells ability to receive positive
signals that influence their differentiation, expansion and
memory formation. This desensitization mechanism may
partially explain why vaccines function poorly in virus-
infected individuals.
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LCMV infection. The percentage (Figure 1E) and total number
(Figure 1F) of donor IFNabR KO P14 cells in recipient host
mice were determined at various times after LCMV infection.
Poly(I:C)-pretreated IFNabR KO P14 cells proliferated to similar
numbers as the control-treated counterparts at both day 7 and 8
post LCMV infection. The fact that these CD8 T cells lacked
expression of the IFNabR and showed no difference in
proliferation between HBSS- and poly(I:C)-primed groups sug-
gested that there was a direct role for type 1 IFN on the CD8 T
cells in this model of immune suppression.
Poly(I:C)-pretreated CD8 T cells are transiently refractory
to IFNb stimulation in terms of STAT phosphorylation
Knowing that type 1 IFN delivered at an optimal time can
provide a positive signal 3 to CD8 T cells and enhance their
proliferation, we questioned whether an out of sequence early
exposure to IFN would interfere with later attempts at IFN
signaling. Type 1 IFN can activate multiple downstream STAT
molecules including STAT1, 3, 4, and 5. Because type 1 IFN
can have both positive and negative effects on T cell expansion,
where recent studies have shown that the specific STAT(s)
activated dictate the outcome, all of the aforementioned STAT
molecules were tested. The phosphorylation of STAT molecules
downstream of the type 1 IFN receptor was thus examined in
CD8 T cells from mice pretreated with either HBSS or
poly(I:C). Mice were inoculated with either HBSS or poly(I:C)
for 1 day, and their splenocytes were isolated and stimulated ex
vivo with mouse IFNb for ,30 min, followed by phosflow to
examine downstream STAT phosphorylation (Figure 2). In
unstimulated (non-IFNb-treated) CD8 T cells, there was very
little phosphoSTAT staining, regardless of the pretreatment
regimen (Figure 2A, shaded histograms). In T cells from
HBSS-treated mice (open bars), the phenotypically naı¨ve
CD44lo CD8 T cells responded strongly to IFNb stimulation
and showed phosphoSTAT 1, 3, 4 and 5 staining well above the
unstimulated controls (solid line, open histograms in Fig-
ure 2A; open bars in Figure 2B–E). However, CD44lo CD8
T cells from mice pre-exposed to poly(I:C) for 1 day were unable
to respond to IFNb stimulation and did not phosphorylate any
downstream STAT molecules tested (dashed line open histo-
gram in Figure 2A; black bars in Figures 2B–2E). Similar to
naı¨ve CD8 T cells, which represent most of the T cells and
which are the focus of this study, CD44hi memory phenotype
CD8 T cells from poly(I:C)-pretreated mice also showed
reduced response to IFNb stimulation in terms of downstream
STAT phosphorylation (Figure S1). Since STAT phosphory-
lation is a transient event, a kinetic analysis of STAT
phosphorylation in cells from HBSS- or poly(I:C)-inoculated
mice stimulated with IFNb for times ranging from 5 minutes to
2 hours was performed. The poly(I:C)-pretreated CD8 T cells
did not phosphorylate downstream STATs above unstimulated
controls at any time point tested (data not shown). The lack of
IFNb- induced phosphoSTAT staining in poly(I:C)-pretreated T
cells suggests that the T cells are unable to respond to IFN and
therefore do not receive either the positive or the negative
effects that type 1 IFN can have on lymphocytes.
To test the duration of this unresponsiveness to IFNb
stimulation, mice were inoculated with HBSS or poly(I:C),
and after 1, 2, or 3 days, their splenocytes were stimulated ex-
vivo with IFNb for ,30 min before staining for phospho-
STATs. As shown in Figure 2, the phenotypically naive CD8
T cells from mice pretreated with poly(I:C) for 1 day did not
respond to IFNb stimulation in terms of STAT phosphorylation
and this is also shown in Figures 3A–D (black bars). Similarly,
CD8 T cells from poly(I:C)-pretreated mice were also less
responsive to IFN stimulation when treated 2 days previously
compared to controls. However, by 3 days after pretreatment,
the CD44lo CD8 T cells from poly(I:C)-treated mice started to
regain the ability to respond to IFNb stimulation and showed
downstream STAT phosphorylation above unstimulated con-
trols. At 3 days, the poly(I:C)-pretreated CD8 T cells
phosphorylated downstream STATs to similar levels as
HBSS-pretreated CD8 T cells for all STATs tested except
STAT4. Memory phenotype CD44hi CD8 T cells pretreated
with poly(I:C) showed a similar transient unresponsiveness to
IFNb stimulation as the naı¨ve CD44lo CD8 T cell response
seen in Figure 3 (data not shown). These data show that the
refractoriness to IFNb stimulation is transient, with kinetics
similar to that of the poly(I:C)-induced impaired proliferation
(Figure 1).
To make sure that STAT molecules were available to be
phosphorylated, total STAT protein levels in naı¨ve CD8 T cells
after different days post HBSS or poly(I:C) inoculation were
determined (Figure 3E–H). After 1, 2, and 3 days of treatment,
total STAT 1, 3, 4 and 5 levels in poly(I:C)-pretreated naı¨ve CD8
T cells were similar to, if not higher than, the control-treated cells.
Total STAT1 expression was higher in poly(I:C)-pretreated naı¨ve
CD8 T cells after 1 day and stayed high through day 3 of
treatment, as compared to STAT1 levels in HBSS-treated CD8 T
cells. Since STAT1 is an IFN-inducible gene [46], higher STAT1
protein expression in poly(I:C)-pretreated CD8 T cells was
expected. These data indicate that the reduced phosphoSTAT
staining found in IFNb-stimulated poly(I:C)-pretreated CD8 T
cells was not due to lower levels of total STAT protein.
Poly(I:C)-pretreated CD8 T cells are responsive to
cytokines other than type 1 IFN
To test if the poly(I:C)-primed CD8 T cells were unresponsive
to other cytokines, splenocytes were stimulated ex vivo with
various cytokines for ,30 min before staining for the appropriate
Figure 1. Poly(I:C)-induced impaired proliferation is transient and requires direct effects of type 1 IFN. (A) Experimental design for
poly(I:C)-induced suppression of proliferation. P14 transgenic CD8 T cells were adoptively transferred into Thy1.2+/Ly5.2+ congenic mice. Recipient
mice were inoculated with HBSS or poly(I:C) for different amounts of time (1, 2, or 3 days), and then splenocytes were isolated and the total frequency
of donor P14 cells was determined by flow cytometry in order to transfer equal numbers of transgenic cells into separate congenic recipients. These
host mice were then infected with 56104 pfu of LCMV and harvested at different days post-infection to determine frequency, number, and function.
(B) P14 transgenic T cells were identified based on Ly5.1+Va2+CD8a+ cells. Representative flow cytometry plots of cells harvested at day 7 post LCMV
infection, gated on CD8a+ cells show frequency of P14 cells that have been HBSS- or poly(I:C)-pretreated for 1, 2, or 3 days. Frequency (C) and total
number (D) of poly(I:C)(black bars)- or HBSS(open bars)-treated cells for 1, 2 or 3 days of pretreatment harvested at day 7 post LCMV infection is
graphed. (E–F) IFNabR KO P14 transgenic CD8 T cells transferred into WT congenic mice before poly(I:C) or HBSS treatment. Equal numbers of IFNabR
KO P14 cells were transferred into separate mice subsequently inoculated with LCMV and harvested at day 7, 8, or 9 post infection. (E) IFNabR KO P14
cells were identified by Va2+Thy1.1+ cells in the representative flow cytometry plots gated on CD8a+ cells. (F) Total number of IFNabR KO P14 cells
calculated at different time points post LCMV infection. Data combined from 2 independent experiments, with n of 4 mice per group (C and D), and
are representative of 3–4 experiments harvested at different days post LCMV infection with n of 3–4 mice per group (E and F).
doi:10.1371/journal.ppat.1004357.g001
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downstream phosphoSTATs. We tested IL-2, IL-6, IL-7, IL-12,
and IL-15, because these cytokines have positive effects on T cell
survival or proliferation. IL-2, IL-7, and IL-12 stimulation did not
elicit positive phosphoSTAT staining in the control- or poly(I:C)-
treated naı¨ve CD8 T cells (Figure S2). Of these cytokines tested,
IL-6 and IL-15 were found to elicit positive phosphoSTAT
staining in HBSS-treated naı¨ve CD8 T cells (open bars) above the
unstimulated control levels (Figure 4A and B). However, unlike
poly(I:C)-pretreated naı¨ve CD8 T cells stimulated with IFNb,
poly(I:C)-pretreated naı¨ve CD8 T cells stimulated with IL-6 (black
bars, Figure 4A) or IL-15 (black bars, Figure 4B) responded just
as well, in terms of phosphorylating downstream STAT3 and
STAT5, respectively, as their control-treated counterparts. Similar
to naı¨ve T cells, CD44hi CD8 T cells also phosphorylated
downstream STAT3 and STAT5 in response to IL-6 and IL-15
stimulation (respectively) from both the HBSS- and poly(I:C)-
treated groups (Figure S3). Together, these data indicate that
poly(I:C) treatment did not make P14 CD8 T cells universally
unresponsive to all cytokines; rather, the impairment was instead
more specific to type 1 IFN. These data suggest that poly(I:C)-
pretreated CD8 T cells, when put into hosts subsequently infected
with LCMV, are not able to respond to the type 1 IFN induced by
the virus, and thus are unable to receive positive signal 3 cytokine
signals.
Figure 2. Poly(I:C)-pretreated CD8 T cells are refractory to IFNb stimulation in terms of STAT phosphorylation. Mice were HBSS- or
poly(I:C)-treated for 1 day. Splenocytes were isolated and either unstimulated, or stimulated ex vivo with IFNb for 30 min and then stained for (B)
pSTAT1,(C) pSTAT3,(D) pSTAT4, and (E) pSTAT5. (A) shows representative histograms gated on CD44lo CD8a+ (naı¨ve) T cells showing pSTAT1, 3, 4 or 5
staining in HBSS– or poly(I:C)-pretreated naı¨ve CD8 T cells unstimulated (shaded histograms) or IFNb stimulated (open histograms). HBSS-pretreated
naı¨ve CD8 T cells stimulated with IFNb shown as solid line histograms, and poly(I:C)-pretreated naı¨ve CD8 T cells stimulated with IFNb shown as
dotted line histogram. (B–E) show pSTAT MFI of naive T cells from unstimulated vs. IFNb stimulated cells HBSS (open bars) or poly(I:C) (black bars)
pretreated for 1 day. Data are representative of at least 4 independent experiments with n of 3 mice per group.
doi:10.1371/journal.ppat.1004357.g002
Out-of-Sequence Signal 3 and Immune Suppression
PLOS Pathogens | www.plospathogens.org 5 September 2014 | Volume 10 | Issue 9 | e1004357
Out-of-Sequence Signal 3 and Immune Suppression
PLOS Pathogens | www.plospathogens.org 6 September 2014 | Volume 10 | Issue 9 | e1004357
Poly(I:C)-pretreated CD8 T cells have decreased IFNAR1
and increased SOCS1 expression
Cytokine signaling must be tightly regulated in order to prevent
over-active and prolonged immune activation. A number of
different mechanisms are in place to limit cytokine signaling,
including reducing cytokine receptor expression, down-regulating
expression of signaling protein components, and up-regulating the
expression of suppressors of cytokine signaling proteins (SOCS)
[47,48]. Reduced STAT protein levels did not account for the
refractoriness to IFNb simulation seen in the poly(I:C)-pretreated
CD8 T cells (Figure 3). To investigate why naı¨ve CD8 T cells pre-
exposed to poly(I:C) were unresponsive to type 1 IFN, but not all
cytokines, cytokine receptor expression was determined. At various
days post HBSS or poly(I:C) treatment, naı¨ve CD8 T cells were
assessed for cytokine receptor signaling components, including
portions of the IL-2, IL-6, IL-7, and IL-15 complexes, and these are
represented in Figure S4. The type 1 IFN receptor is comprised of
two components, IFNAR1 and IFNAR2 [37]. Naı¨ve CD8 T cells
from mice inoculated with poly(I:C) for one day had much lower
expression levels of IFNAR1, compared to the HBSS-treated cells
(Figure 5A–5B). However, IFNAR1 expression levels returned to
control-treated levels by 2 days post treatment. The CD44hi CD8 T
cells had similar kinetics of IFNAR1 expression as the naı¨ve CD8 T
cells, showing slightly reduced receptor expression with 1 day
treatment of poly(I:C) but not 2 or 3 days of treatment (Figure S5).
Thus, unresponsiveness to type 1 IFN at day 1 correlated with the
lack of expression of the IFN receptor.
Since poly(I:C)-pretreated CD8 T cells were still less responsive to
IFNb stimulation, as measured by STAT phosphorylation, 2 days
after poly(I:C) treatment (Figure 3), there were likely other
suppressive mechanisms to limit IFNb responsiveness, in addition
to the reduced receptor expression shown in Figure 5A and B.
SOCS proteins are known to inhibit cytokine receptor signaling by
acting at many different steps in the JAK/STAT signaling pathway
[47]. SOCS1 inhibits type 1 IFN signaling by binding to the
receptor-associated JAK protein TYK2, thus blunting IFN receptor
signaling [49]. Naı¨ve CD44lo CD8 T cells that were sorted from
mice inoculated with HBSS or poly(I:C) for 1 day showed a 7-fold
relative increase in SOCS1 message expression after poly(I:C)
treatment. We next utilized the well-established protocol for staining
for phosphorylated proteins to identify intracellular levels of
SOCS1. SOCS1 expression was determined in naı¨ve CD8 T cells
from poly(I:C)- or HBSS-inoculated mice 1, 2, or 3 days after
treatment (Figure 5C–D). Indeed, at both 1 and 2 days after
poly(I:C) treatment, naı¨ve CD8 T cells had higher expression of
SOCS1 compared to the control-treated cells. However, by 3 days
of pretreatment, there was no longer a significant difference in
SOCS1 expression between control and poly(I:C)-treated CD8 T
cells. CD44hi CD8 T cells also showed increased SOCS1 protein
levels (Figure S5). This suggests that a combination of a decrease in
IFNabR expression and an increase in SOCS1 expression may
account for the observed refractoriness to IFNb stimulation. These
results correlated kinetically with refractoriness to IFNb stimulation
(Figure 3) and to the suppressed proliferation seen in poly(I:C)-
pretreated CD8 T cells (Figure 1). These experiments do not
definitively parse out the relative contributions of decreased
receptor expression vs. inhibitory molecule contribution to T cell
refractoriness to IFN stimulation, but the results are very consistent
with previous work in more tractable systems studying the
mechanism of unresponsiveness to IFN [49–51]. Further, they
clearly show that this unresponsiveness is not due to decreases in
overall STAT protein expression.
Poly(I:C)-pretreated CD8 T cells behave similarly to 2-
signal-stimulated rather than 3-signal-stimulated CD8 T
cells
Because the suppression of proliferation of poly(I:C)-pretreated
CD8 T cells correlated with refractoriness to IFNb stimulation, we
Figure 4. Poly(I:C)-pretreated CD8 T cells can respond to other
cytokines, including IL-6 and IL-15. Mice were inoculated with
HBSS (open bars) or poly(I:C) (black bars) for 1 day. Splenocytes were
isolated and either unstimulated, stimulated with IL-6 (A) or IL-15 (B)
and then stained for downstream pSTAT3 (A) or pSTAT5 (B).
Splenocytes were gated on CD44lo CD8a+ T cells, and plotted for
pSTAT MFI. Data are representative of at least 2 independent
experiments with n of 3 mice per group.
doi:10.1371/journal.ppat.1004357.g004
Figure 3. Refractoriness to IFNb stimulation is transient and not due to reduced total STAT levels. (A–H) Mice were HBSS- (open bars) or
poly(I:C)- (black bars) treated once 1, 2, or 3 days prior to isolation. (A–D) Splenocytes were isolated, stimulated ex vivo with IFNb for 30 min and then
stained for phosphoSTATs. Cells were gated on CD44loCD8a+ T cells plotting pSTAT MFI after IFNb stimulation showing MFI for (A) pSTAT1, (B)
pSTAT3 (C) pSTAT4 or (D) pSTAT5. (E–H) Splenocytes were stained ex vivo for total STAT proteins including (E) STAT1, (F) STAT3, (G) STAT4, and (H)
STAT5. Plots showing total STAT MFI, gated on CD44loCD8a+T cells. Data are representative of 2 independent experiments with n of 3 mice per
group.
doi:10.1371/journal.ppat.1004357.g003
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hypothesized that poly(I:C)-pretreated CD8 T cells were unable to
receive the positive effects that type 1 IFN exerts as a signal 3
cytokine when delivered in the proper sequence. This hypothesis
would suggest that poly(I:C)-pretreated P14 cells would behave
similarly to 2-signal only CD8 T cells, rather than 3-signal CD8 T
cells. Thus, we examined their effector phenotype and their
abilities to divide, produce cytokines, degranulate, and express the
survival protein BCL3 in response to antigen exposure.
Studies have shown that 2-signal CD8 T cells divide similarly to
3-signal CD8 T cells but have defects in survival [27]. We
therefore tested whether the impairment in proliferation seen in
poly(I:C)-pretreated CD8 T cells was due to division or survival
defects. A similar experimental setup as shown in Figure 1A was
used, but after inoculation with HBSS or poly(I:C), congenic P14
CD8 T cells were labeled with CellTrace violet and transferred
together into the same recipients to track cell division during
LCMV infection. Cells were harvested at days 3 and 4 post
infection, and CellTrace violet dilution was measured. Because we
were looking at early days post infection, a larger number of
transgenic cells was transferred than what would normally be
considered physiologically relevant in order to quantify early cell
division. Neither the poly(I:C)- nor the HBSS-pretreated P14 cells
diluted CellTrace violet in naı¨ve mice, indicating that they did not
divide (Figure 6A). At day 3 post infection, the control-treated
P14 cells diluted more CellTrace violet, indicating they had
undergone more cell divisions compared to the poly(I:C)-
pretreated P14 cells (Figure 6A–C). However, by day 4 post
LCMV infection, the division profiles of both HBSS-and poly(I:C)-
pretreated P14 cells appeared similar. Although the percentage of
cells that divided was statistically similar between the two groups
(Figure 6B), the proliferation index of poly(I:C)-pretreated P14
cells was lower compared to HBSS-treated cells (Figure 6C). The
proliferation index represents the average number of divisions of
the cells that have undergone at least one division. These results
show that poly(I:C)-pretreated CD8 T cells have a delay in the
number of cell divisions.
If a delay in cell division were the only thing contributing to the
suppression of proliferation, at later time points post infection the
expansion of poly(I:C)-pretreated CD8 T cells might eventually
reach the same level as the control-treated cells. Therefore, a time
course of HBSS- or poly(I:C)-pretreated P14 CD8 T cell
expansion in response to LCMV infection was performed. The
peak of expansion of poly(I:C)-pretreated P14 CD8 T cells was
delayed (day 9) compared to HBSS-pretreated P14 CD8 T cells
(day 7), but the magnitude of the response was still reduced in the
poly(I:C)-pretreated cells (Figure 6D). In addition, out-of-se-
quence P14 cells showed decreased memory frequencies (Fig-
ure 6E) and number (data not shown) compared to their control
Figure 5. Poly(I:C)-pretreated CD8 T cells have decreased type 1 IFN receptor expression and increased SOCS1 expression. Mice
were HBSS- (open bars) or poly(I:C)- (black bars) treated for 1, 2, or 3 days. Splenocytes were isolated and stained for type 1 IFN receptor expression
(A–B) or SOCS1 expression (C–D). (A) Representative histograms showing IFNAR1, gating on CD44lo CD8a+ T cells and IFNAR1 MFI (B). (C)
Representative histograms of SOCS1 expression, gating on CD44lo CD8a+ T cells. (D) SOCS1 MFI in poly(I:C)- or HBSS-treated cells after 1, 2, or 3 days
of pretreatment. Data are representative of 2 independent experiments with n of 3 mice per group.
doi:10.1371/journal.ppat.1004357.g005
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treated counterparts at multiple time points tested. This suggests
that the defects in clonal expansion were not solely due to a delay
in cell division but may also be due to other factors such as defects
in cell survival. In vitro and in vivo studies by others found that
survival of activated T cells in response to signal 3 cytokines and
adjuvants was in part due to an increase in the IkB family member
BCL3 and that cells lacking signal 3 cytokines have reduced
expression of BCL3 [31–33]. To determine if the poly(I:C)-treated
virus-stimulated T cells resembled two signal only T cells in this
respect, the expression of BCL3 was thus determined in HBSS-
control or poly(I:C)-pretreated P14 CD8 T cells after LCMV
infection. Indeed, a lower percent of poly(I:C)-pretreated P14 cells
up-regulated BCL3 than HBSS-treated P14 cells at days 4, 5 and 6
post LCMV infection (Figure 6F). Additionally, the BCL3 MFI
of poly(I:C)-pretreated P14 CD8 T cells was lower than in HBSS
control-treated cells (Figure 6G). Combined, these results showed
that, similar to 2-signal CD8 T cells, out-of-sequence signal 3-
stimulated P14 CD8 T cells had a delay in cell division when
compared to CD8 T cells that receive all 3 signals in the correct
order, and that they had defects in a survival protein that may
limit the ability of these cells to clonally expand.
To further support the hypothesis that out-of-sequence signal 3
CD8 T cells do not receive the positive effects that type 1 IFN can
have as a signal 3 cytokine during acute virus infection, and
thereby contribute to suppression of proliferation, we determined
the frequency of poly(I:C)- or HBSS-pretreated P14 cells after
cognate peptide stimulation. Congenic P14 mice were directly
treated with HBSS or poly(I:C) for 1 day, and their splenocytes
were transferred together into the same recipients that were naive,
that received 13mer GP33–45 peptide or that were inoculated with
LCMV. Here the LCMV infection should induce high levels of
type 1 IFN, whereas the peptides would be poor type 1 IFN
inducers. Figure 6H shows that at all time points tested,
poly(I:C)-pretreated P14 cells expanded to similar levels as
HBSS-pretreated P14 cells in mice that only saw antigen (13mer
GP33–45) and did not have a major inflammatory response.
However, poly(I:C)-pretreated P14 cells had defects in expansion
in response to the IFN-inducing LCMV infection compared to
control treated cells (note the different axis for GP33 peptide or
LCMV inoculation). Given that poly(I:C)-pretreated P14 cells
expanded to similar levels in response to antigen only but had
defects in expansion in response to antigen and inflammation (i.e.
live virus infection), these results further support our hypothesis
that out-of-sequence CD8 T cells are unable to receive positive
effects of signal 3 cytokines during acute infections.
Signal 3 cytokines have been shown to regulate the differenti-
ation of CD8 T cells into distinct effector populations including
EEC, SLEC and MPEC [17,24,34,35]. Therefore, we examined
the ability of poly(I:C)-pretreated CD8 T cells to differentiate into
EEC, SLEC and MPEC populations, which can be distinguished
based on expression of KLRG1 and CD127 [30,34,52]. A similar
experimental model was used as shown in Figure 1A, where WT
or IFNabR KO P14 cells were transferred into mice for 1 day of
treatment with poly(I:C) or HBSS prior to a second transfer into
congenic hosts that were subsequently inoculated with LCMV. At
different days post infection, splenocytes were isolated and stained
for KLRG1 and CD127. At day 7 post infection, the IFNabR KO
P14 CD8 T cells had similar proportions of SLEC (KLRG1hi,
CD127lo), MPEC (KLRG1lo, CD127hi) and EEC (KLRG1lo,
CD127lo), regardless of the pretreatment regime. These data are
consistent with other results showing that type 1 IFN is important
for SLEC differentiation in various infection models [25,35].
However, poly(I:C)-pretreated WT P14 CD8 T cells had reduced
proportions of SLEC populations and increased EEC proportions
compared to the HBSS-pretreated WT P14 CD8 T cells
(Figure 7A). This data supports our hypothesis that the out-of-
sequence CD8 T cells behave more similar to 2-signal only CD8 T
cells (IFNabR KO P14 cells) in terms of effector cell differenti-
ation. The defect in SLEC differentiation in poly(I:C)-treated cells
can be seen as early as day 5 post infection, but is more dramatic
at days 6 and 7 post infection (Figure 7B). The proportion of
MPECs were generally similar to or slightly elevated in poly(I:C)-
pretreated P14 cells as compared to control-treated counterparts at
days 5–7 post infection (data not shown). These data show that in
addition to CD8 T cells requiring signal 3 cytokines for proper
effector cell differentiation, they also need to see the signals in the
appropriate order.
In some infection models, two-signal CD8 T cells can produce
similar proportions of cytokines as compared to 3-signal CD8 T
cells (VSV), but other infection models show reduced cytokine
production (Listeria) [25,27]. Therefore, we compared poly(I:C)-
and HBSS-treated cells for their ability to produce the effector
cytokines TNF and IFNc. A similar experimental model was used
as shown in Figure 1A, where P14 cells were transferred into
mice for 1 day of treatment with poly(I:C) or HBSS or P14 mice
were treated directly with poly(I:C) or HBSS prior to transferring
cells into congenic hosts that were subsequently inoculated with
LCMV. At day 5 post infection, splenocytes were isolated and
stimulated ex vivo with or without cognate peptide GP33 for
5 hours. Using naı¨ve CD8 T cells, isotype controls and fluorescent
minus one staining to distinguish positive vs. negative staining, the
poly(I:C)-pretreated P14 cells produced similar frequencies of TNF
and IFNc compared to control-treated P14 cells after in vitro
LCMV GP33 peptide stimulation (Figure 7C). Plotting the
proportion of double cytokine producers (TNF and IFNc)
(Figure 7D) revealed no significant difference in the ability of
these cells to produce effector cytokines. Using CD107a and b as
markers for degranulation, we found that poly(I:C)-pretreated P14
Figure 6. Poly(I:C)-pretreated P14 CD8 T cells have a delay in division and reduced BCL3 expression. (A–C) Congenic transgenic P14
mice were HBSS or poly(I:C) treated. One day after treatment P14 cells were labeled with CellTrace Violet, and similar numbers of HBSS- and poly(I:C)-
pretreated cells were transferred into the same recipients, which were subsequently inoculated with LCMV. (A) Representative CellTrace Violet
dilution profiles shown for different days post infection. Percent divided (B) and proliferation index (C) of P14 cells pretreated with HBSS (open bars)
or poly(I:C) (black bars) at day 3 and 4 post infection. (D–G) Equal numbers of HBSS (open bars) - and poly(I:C) (black bars)-pretreated P14 CD8 T cells
transferred into the same or different recipients which were subsequently infected with LCMV. (D–E) Spleens were harvested at days 5, 7, 9, 12, 15, 20,
30, 62, or 77 post infection, and the frequency of donor P14 cells of the total CD8 population is graphed. P14 cells were transferred into the same
hosts when spleens were harvested from day 5-day 20 post infection and different hosts when harvested at day 30 or later. (F–G) Cells were harvested
at day 4, 5, or 6 post LCMV infection. Representative flow cytometry plots showing CD44 and BCL3 expression (F) and BCL3 MFI (G) of the donor P14
cells is graphed. (H) P14 mice were either HBSS (open bars) or poly(I:C) (black bars) treated for 1 day, after which equal numbers of P14 cells were
transferred together into the same recipients that remained uninfected, that received 5 mg 13mer GP33–45 peptide, or that were infected with LCMV.
Spleens were harvested at days 3–5 post peptide inoculation and/or day 7 post LCMV infection. The appropriate naı¨ve control for was used to
calculate the fold expansion. Data are representative of 2 individual experiments with n of 4–6 per group (A–C), one experiment with n of 5 per group
(D), 3 individual experiments with n of 4–5 per group (E), and one experiment with n of 3–5 per group (F–G). Data were combined from 3 individual
experiments, each with 2 time points tested with n of 5 mice per group (H).
doi:10.1371/journal.ppat.1004357.g006
Out-of-Sequence Signal 3 and Immune Suppression
PLOS Pathogens | www.plospathogens.org 10 September 2014 | Volume 10 | Issue 9 | e1004357
Out-of-Sequence Signal 3 and Immune Suppression
PLOS Pathogens | www.plospathogens.org 11 September 2014 | Volume 10 | Issue 9 | e1004357
cells stained to a similar extent, if not slightly more, than HBSS-
treated cells in response to GP33 peptide stimulation (Figure 7E–
7F). However, poly(I:C)-pretreated P14 CD8 T cells had
substantially lower levels of granzyme B expression than control-
treated cells at day 5 post infection (Figure 7E). Reduced
granzyme B expression in the out-of-sequence CD8 T cells was
seen as early as day 4 post infection and lasted at least until day 6
post infection (Figure 7G). KLRG1 expression in CD8 T cells is
considered a marker for effector function, and there was a positive
correlation between KLRG1 expression and granzyme B expres-
sion (R square = 0.8563, p,0.0001) (Figure 7H). Since granzyme
B expression has been used as a correlative marker for cytotoxic
capability [36], this suggests that poly(I:C)-pretreated CD8 T cells
have reduced cytolytic function compared to HBSS-treated CD8
T cells. These data showing similar cytokine production but
reduced granzyme B expression are consistent with published
phenotypes for CD8 T cells that only receive 2 signals [25,27].
A new method to study effector cell function is the trogocytosis
assay, whereby target cells are labeled with a membrane dye,
mixed with cytotoxic effector cells for 1 hr, and then examined for
the transfer of dye to a flow cytometry-defined effector cell
population [53,54]. This is an indicator of how aggressively the
effector cells are attacking the targets. Figure S6 shows that the
poly(I:C)-pretreated P14 cells, 5 days after LCMV infection, had
modest but statistically significant reduced ability to acquire the
dye from GP33-pulsed RMA cells, when compared to the HBSS-
pretreated donor T cells. Reduced incorporation of the lipid dye is
an indicator of reduced effector cell function [55,56].
We tested whether these donor poly(I:C)-pretreated T cell
responses, which were dramatically reduced in number and
modestly reduced in effector function, would affect viral load
differently than that in mice receiving HBSS-treated cells. Mice
receiving either HBSS-pretreated or poly(I:C)-pretreated P14 CD8
T cells were subsequently infected with LCMV, and viral titers
were examined at different time points post infection. As early as
day 4 post infection, mice receiving poly(I:C)-pretreated P14 cells
had modest but statistically significant increased viral titers
compared to mice receiving control treated P14 cells in the fat
pad (4.760.1 vs. 4.360.08 log pfu, two independent experiments
combined for n = 10 per group) respectively (p = 0.0082). In
addition, at day 6 post infection, there was a modest but significant
increase in viral load in the spleen and liver in mice receiving
poly(I:C)-pretreated P14 CD8 T cells (4.260.07 log pfu in the
spleen, 4.260.08 log pfu in the liver) compared to mice receiving
HBSS-pretreated P14 cells (3.860.12 log pfu in the spleen,
3.860.08 log pfu in the liver) (3 independent experiments
combined for n = 14–15, p = 0.0197 (spleen) and p = 0.0074
(liver)). These differences in viral titer are admittedly small, but
they are statistically significant and occur in environments where
normal endogenous host T cell responses are simultaneously
occurring.
Discussion
Transient states of immune suppression occur during many
acute viral infections, and it has long been known that individuals
should not get vaccinated when they are sick. Virus-induced
immune suppression was first noted over 100 years ago [1], and
more recent studies have shown it to be a common element of
many viral infections and often be associated with suppressed T
cell proliferation in response to antigens and mitogens. In vitro
studies had suggested that AICD contributed to this inhibition of
T cell proliferation [2,8,9,57], and other studies implicated
impaired antigen-presenting cell function [10,11,58], induction
of immunosuppressive cytokines like IL-10, [12], and perhaps the
competition for T cell growth factors could play a role. While
studying viral infection models, we recently found that a general
mechanism of virus-induced immune suppression could be linked
to type 1 IFN, normally induced at high quantities in most viral
infections [13]. This was somewhat surprising, given that type 1
IFN has been described as a signal 3 cytokine, which drives the
expansion and differentiation of T cells after they have encoun-
tered cognate ligand (signal 1) and co-stimulation (signal 2). The
primary observation of the present report is that if T cells are
exposed to type 1 IFN inducers before exposure to cognate ligand,
they lose their sensitivity to further IFN stimulation and do not
receive the benefits of a signal 3 cytokine. Instead, they behave like
T cells receiving only two signals, with defects in effector cell
differentiation, reduced effector function, lower expression of a
pro-survival protein, and limited clonal expansion.
Dating back to the early days of IFN therapy in humans, it has
long been known that lymphocytes like NK cells become
hyporesponsive to treatment, and IFN, like many other cytokines,
can render treated cells resistant to further IFN stimulation by
down regulating the IFN receptor and by inducing factors like
SOCS1 that impair IFN-induced signal transduction [47,48]. We
show here that this is the case with virus-specific T cells, and that
these T cells pre-exposed to IFN fail to derive the benefit of the
positive signal 3 effects of IFN signaling. The implications of this
phenomenon are widespread. Because IFN is induced so rapidly
during viral infections, one can deduce that the T cells that
encounter antigen in the first day or two of infection would
respond more impressively than ‘‘late-comer’’ virus-specific T cells
stimulated later in infection. Thus, the dynamics of how much
antigen is synthesized and presented vs. how much and how
quickly IFN is induced may dictate the efficacy of the host
response. Secondly, the T cell response to many acute infections,
at least in mouse models, is relatively ordered and undergoes a
rather synchronized contraction from 6–9 days post-infection.
How can this occur when the amount of T cell proliferation is a
programmed event [59–62] and when different T cells should
encounter antigen at different time periods? We would argue that
the late-comer T cells, because of their previous exposure to IFN,
would not undergo as many divisions and possibly have lower
Figure 7. Poly(I:C)-pretreated P14 CD8 T cells have reduced effector function. (A–B, E–H) WT or IFNabR KO P14 cells were transferred into
congenic mice that were inoculated with HBSS or poly(I:C), and 1 day later equal numbers of P14 cells were transferred into separate congenic mice
subsequently infected with LCMV. (C–D) P14 mice were directly treated with poly(I:C) or HBSS for 1 day prior to transfer into congenic mice that were
infected with LCMV. Cells were harvested at various days post infection (day 4, 5, 6, or 7). (A–C) cells were unstimulated or (C–H) stimulated ex vivo
with GP33 peptide. (A) Representative flow cytometry plots gating on IFNabR KO P14 cells (Va2+Thy1.1+ CD8a+) or WT P14 cells (Va2+Ly5.1+CD8a+)
showing KLRG1 and CD127 expression at day 7 p.i. (gates drawn using naı¨ve CD8 T cells) (B) Percent of WT donor P14 cells that express the SLEC
phenotype (KLRG1hi/CD127lo) at different days post infection. (C) Representative flow cytometry plots gating on P14 cells (Va2+Ly5.1+CD8a+)
showing TNF and IFNc production at day 5 p.i. (D) Frequency of HBSS- (open bars) or poly(I:C)- (black bars) pretreated P14 CD8 T cells that produce
both TNF and IFNc. (E) Representative histograms for either CD107a/b or granzyme B staining in poly(I:C)- (open solid lines) or HBSS- (shaded dashed
lines) pretreated P14 CD8 T cells. Total frequency of HBSS- (open bars) or poly(I:C)- (black bars) P14 cells producing CD107a/b (F) or MFI of granzyme B
at different time points post infection (G). (H) Correlation between frequency of granzyme B+ P14 cells and KLRG1+ P14 cells at day 5 post infection.
Data are representative of at least 2 individual experiments with n of 3–5 mice per group.
doi:10.1371/journal.ppat.1004357.g007
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survival properties, thereby enabling them to contract when the
rest of the T cells do. Third, we would argue that naı¨ve or memory
T cells specific to third party antigens would not respond well to a
cognate antigen stimulus if they were first exposed to the IFN
milieu of a viral infection and then stimulated with antigen. This
failure to respond to recall antigens, such as tetanus toxoid or
tuberculin, is a common feature of virus-induced immune
suppression in humans, and the weak efficacy of vaccines in
already infected individuals may well be a function of the same
problem [63–65]. Finally, under conditions when a host develops a
persistent viral infection there would be a chronic stimulation of
the type 1 IFN response, and such hosts would probably not
immunologically respond well to either the antigens of the
infecting virus or to third party antigens on challenge. This weak
response to third party antigens is not only seen during persistent
viral infections but also during chronic autoimmune diseases, such
as lupus erythematosus, where signal 3 cytokines may be
chronically produced [66,67]. We therefore suggest that the
elimination of signal 3 stimulation by out-of-sequence exposure to
the signal 3 stimulant, in this case IFN, would be a common factor
disrupting T cell responses in the context of acute or persistent
viral infections.
This generalized IFN-induced impairment of proliferation is
one example of how out-of-sequence signaling can alter responses
to cognate antigen exposure. On the other hand, virus-induced
inflammatory environments can alter the response of bystander
CD8 T cells not specific for the infecting virus to third party
cognate antigens by driving the T cells down a different
differentiation pathway [45]. Our previous studies showed that
transgenic CD8 T cells exposed to virus-induced inflammatory
environments were sensitized to undergo rapid effector function
such that upon stimulation with cognate antigen they produced
cytokines including granzyme B and IFNc within a few hours and
without a need for cell division. The sensitization to rapid effector
function was most dramatic with viruses that induced a strong
type 1 IFN response, and this event could also be induced by
poly(I:C). We do not know if the CD8 T cells sensitized to rapid
effector function are in fact the same cells that ultimately are
suppressed in proliferation. However, we do know that these two
changes in T cell response to cognate antigen stimulation occur
by very distinct mechanisms and occur in virus-induced
inflammatory environments; consequently, the impairment of
proliferation may contribute to generalized IFN-induced immune
suppression, even though there may be an initial transient
activation of the T cells.
Type 1 IFN can have both stimulatory and inhibitory effects on
CD8 T cell proliferation, but here it was initially unclear if
poly(I:C)-pretreated CD8 T cells were receiving direct inhibitory
signals or fewer stimulatory signals from IFN. Since type 1 IFN
signaling can act through multiple STATs, each capable of
altering cell fate, it might have been expected that poly(I:C)-
pretreated CD8 T cells would have had different STAT
phosphorylation in response to IFNb stimulation. Recent work
has shown that virus-specific CD8 T cells down-regulate total
STAT1 and up-regulate STAT4, so that when IFN signals though
the IFN receptor the anti-proliferative effects of STAT1 will be
overcome by the positive effects mediated through STAT4
[38,43]. Therefore, poly(I:C)-pretreated CD8 T cells could have
had more pSTAT1 and less pSTAT4 than control-treated cells
after IFNb stimulation. However, this was not the case at the time
points studied, as phosphorylation of all tested STATs was
reduced (Figures 2 and 3). The fact that all pSTATs were
reduced in poly(I:C)-pretreated CD8 T cells suggested that IFN
was not having a direct negative effect other than by desensitizing
cells to the positive effects that a later exposure to IFN could
mediate.
It should be noted that not only were naı¨ve CD8 T cells
unresponsive to IFNb stimulation after poly(I:C) treatment, but
CD4 T cells and NK cells were also refractory to further IFNb
stimulation in terms of STAT phosphorylation (data not shown).
Type 1 IFN has been shown to act directly on CD4 T cells, NK
cells and B cells to promote effector function [68–70], and these
results may indicate that in addition to poly(I:C) inducing
inhibitory effects on CD8 T cell proliferation, it may also have
suppressive effects on other lymphocyte populations that utilize
IFN at another time for their activation. Indeed, reduced antibody
production by B cells and lower NK cell cytotoxicity have been
seen under conditions of virus-induced immune suppression
[69,71].
Antigen and co-stimulatory molecules provide proper signals for
T cell activation and differentiation, but more recent studies have
focused on the role for inflammatory cytokines in these processes.
We find here an additional layer of complexity in that the timing
of T cell exposure to signal 3 cytokines is extremely important. If
CD8 T cells are unable to receive the positive effects of type 1 IFN,
as shown in this study, they should behave more like T cells that
only received 2 signals, rather than 3 signals. This was the case, as
the out-of-sequence signal 3 CD8 T cells had defects in SLEC
differentiation and effector function. Poly(I:C)-pretreated CD8 T
cells degranulated, as shown by CD107a/b staining, but they had
reduced granzyme B expression (Figure 7), suggesting that
poly(I:C)-pretreated CD8 T cells have lower cytolytic capabilities
at day 5 post-infection. This is consistent with the phenotype of
signal 3-lacking T cells but inconsistent with our observation that
prior signaling with IFN can sensitize a CD8 T cell to rapid
effector function on exposure to cognate ligand. That enhanced
effector function, however, was examined shortly after TCR (a few
hours) stimulation and not examined at day 5 post infection. Thus,
out of sequence exposure to IFN may initially stimulate effector
function of CD8 T cells but not sustain it as they poorly
proliferate.
Another hallmark of 2-signal only CD8 T cells is limited clonal
expansion, which in many cases is attributed to decreased survival.
Although the exact mechanism is unknown, BCL3 prolongs the
survival of activated CD8 T cells after signal 3 cytokine addition or
CpG adjuvant administration [31–33,72]. The IFN-induced
suppression of proliferation seen here may also have been due to
a decrease in survival. This idea was supported by poly(I:C)-
pretreated CD8 T cells having lower expression of the pro-survival
protein BCL3 (Figure 6). We show here, that poly(I:C)-pretreated
P14 cells also had a delay in cell division compared to HBSS-
treated cells in response to LCMV infection (Figure 6). Interest-
ingly, the delay in cell division of poly(I:C)-pretreated P14 cells is
seen at day 3 post infection, but not at day 4 post infection,
matching the kinetics of the timing of the ability of CD8 T cells to
respond to IFNb signals by phosphorylating downstream STATs
(Figure 3). The positive effects that an inflammatory environment
can have on CD8 T cell expansion is also shown here, whereby
P14 T cells expanded ,20 fold in response to GP33 peptide, but
expanded more than 30,000 fold in response to LCMV infection.
The facts that poly(I:C)-pretreated P14 cells are suppressed in
proliferation in response to LCMV infection but not to GP33
peptide stimulation support the idea that the refractoriness to IFN
stimulation contributes to reduced expansion (Figure 6). This
mechanism of IFN-induced immune suppression may explain how
many virus infections can inhibit T cell responses, by limiting the
ability of T cells to receive stimulatory effects from the
environment.
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To summarize, if CD8 T cells see signal 3 first, they become
refractory to further IFN stimulation and are unable to receive the
positive signals that type 1 IFN can provide when delivered at the
proper time after antigen and co-stimulation. This limits their
ability to clonally expand, to sustain cytolytic capabilities, and
form memory. Our studies show lower proportions and numbers
of out-of-sequence CD8 T cells at different stages of memory
formation (Figure 6E), including as late as 11 weeks post
infection. Preliminary data show that the out-of-sequence CD8
T cells that do form memory are able produce similar proportions
of cytokines, when stimulated ex vivo, compared to memory cells
from the control environment (data not shown), but the
effectiveness of these memory cells has not been further
investigated. The efficacy of an out-of-sequence CD8 T cell
memory response to secondary challenge is important to study but
is beyond the scope of the paper, whose focus was to examine why
IFN causes naı¨ve T cells to function poorly during the context of
an acute viral infection. Thus, under circumstances when CD8 T
cells can receive positive signals, such as during an infection or
vaccination with adjuvants, out-of-sequence signals can have a
profound effect on CD8 T cell expansion and activation. This out-
of-sequence inhibition of T cell proliferation may account for the
more general immune suppression seen in many acute virus
infections known to induce type 1 IFN. This mechanism of CD8 T
cell suppression would be expected to contribute to the reduced
efficacy of vaccines when they are administered during an acute
infection.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the University of Massachusetts Medical
School Institutional Animal Care and Use Committee, Docket #
A-305, Animal Welfare Assurance Number A-3306-01.
Mice
C57BL/6J (Ly5.2+) male mice were purchased from The
Jackson Laboratory (Bar Harbor, ME). Ly5.1 and Thy1.1 P14
[73] TCR-transgenic mice were bred in the Department of
Animal Medicine at the University of Massachusetts Medical
School (UMMS). The P14 transgenic mice were bred onto the
B6.IFNabR KO background to generate P14 CD8 T cells that
lacked IFNabR [13,74].
Virus stocks and peptides
Lymphocytic choriomeningitis virus (LCMV), strain Armstrong,
was propagated in baby hamster kidney (BHK21) cells, as
previously described [75,76]. Mice were injected intraperitoneally
(i.p.) with 56104 pfu of LCMV. Organ homogenate viral titers
were determined by plaque assay using Vero cells. To activate P14
CD8 T cells without a virus-induced inflammatory response, mice
were inoculated intravenously (i.v.) with 5 mg (diluted in HBSS) of
a 13-mer peptide (GP33–45) (KAVYNFATCGIFA) from the
LCMV glycoprotein. RMA cells were labeled with the minimal
GP33 epitope (KAVYNFATC), or the Vaccinia Virus K3L
epitope (YSLPNAGDVI) at 1 mM concentration.
Poly(I:C) and cytokines
Poly(I:C) was purchased from InvivoGen (SanDiego, CA) and
diluted in HBSS for a concentration of 1 mg/ml. Mice were either
inoculated with 200 ml HBSS or 200 mg poly(I:C) i.p. Mouse IFNb
was purchased from PBL Interferon Source. Cytokines: IL-2 was
purchased from BD Biosciences, IL-6 and IL-12 were purchased
from R&D, and IL-7 and IL-15 were purchased from PeproTech,
INC. Splenocytes were stimulated ex vivo with cytokine concen-
trations of 1000 U/ml IFNb, or 10 mg/ml of IL-2, IL-6, IL-7, IL-
12, or IL-15 at 37uC for ,30 minutes.
Adoptive transfers
For the dual transfer experiments, splenocytes (1–36107) from
WT or IFNabR KO P14 transgenic mice (Ly5.1+ or Thy1.1+)
were adoptively transferred i.v. into congenic C57BL/6J (Ly5.2+
Thy1.2+) mice. One day after transfer, mice were inoculated i.p.
with HBSS or poly(I:C), and at various times post treatment (1
day,18–24 hours, 2 days,40–48 hours, 3 days,64–72 hours)
spleens were isolated, and the frequency of transgenic P14 CD8 T
cells was determined by flow cytometric staining of Va2, CD8a,
and Ly5.1 or Thy1.1. Equal numbers (,10.000) of P14 CD8 T
cells were transferred i.v. into congenic B6 hosts immediately prior
to infection with LCMV. For single transfer experiments, Ly5.1 or
Thy1.1 P14 TCR transgenic mice were inoculated with HBSS or
poly(I:C) i.p. for various times, after which, the same protocol was
used as the dual transfer method to transfer in equal numbers of
P14 transgenic T cells. In experiments where control- and
poly(I:C)-treated transgenic P14 cells were transferred into the
same recipients subsequently infected with LCMV, a total of
10,000 P14 cells were transferred. In experiments where HBSS-
and poly(I:C)- treated P14 cells were transferred into the same
recipients receiving 13-mer GP33–45 peptide, ,2–46105 P14 cells
were transferred i.v. This higher amount was necessary for the
peptide-stimulated cells to be detected. Prior to any adoptive
transfer, single cell suspensions were prepared by lysing red blood
cells with 0.84% NH4Cl solution and washing with HBSS.
Where described, cells were labeled with 5 mM CellTrace Violet
(Invitrogen) by incubating at 37uC for 15 min. Cells were then
washed with HBSS at least 2 times prior to adoptive transfer. A
larger number of transgenic P14 cells (,16106 per group) were
transferred into hosts to identify virus-specific cells early after
LCMV infection.
Surface and intracellular cytokine staining
Spleen leukocytes were stained with a combination of fluores-
cently labeled monoclonal antibodies (MAb) specific for CD8a
(53-6.7), Va2 TCR (B20.1), Ly5.1 (A20), Thy1.1 (HIS51), CD44
(IM7) KLRG1 (2F1), CD127 (A7R34), and IFNAR1 (MAR1-5A3)
for 20 min at 4uC. Intracellular cytokine staining was performed
as described previously [45]. Briefly, spleen leukocytes (2–46106)
were plated with or without 5 mM synthetic peptide stimulation in
the presence of GolgiPlug (BD Pharmingen) and human rIL-2 for
4 to 5 hours at 37uC. After stimulation, cells were washed in Flow
Cytometry Buffer (2% FCS in HBSS), blocked with a-FcR (2.4G2)
and stained with a combination of fluorescently labeled mAbs
listed above. After surface staining, spleen leukocytes were fixed
and permeabilized with Cytofix/Cytoperm (BD Bioscience) for
20 min at 4uC and then stained with a combination of
fluorescently labeled MAb specific for TNF (MP6-XT22), IFNc
(XMG1.2), and Granzyme B (GB11, Invitrogen). To identify cells
undergoing Ag-induced degranulation, splenocytes were stimulat-
ed as stated above with addition of CD107a (1D4B) and CD107b
(ABL-93). All MAbs were purchased from eBioscience, SanDiego,
CA, BioLegend, San Diego, CA, or BD Bioscience, San Diego,
CA. unless otherwise noted.
Freshly stained and previously fixed samples were acquired
using a BD Bioscience LSR II flow cytometer with FACS Diva
software. Data were analyzed with FlowJo software (Tree Star
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Inc., Ashland, OR). To determine percent divided and prolifer-
ation index, the proliferation function from FlowJo was applied to
samples.
Phosflow and intracellular protein staining
To identify intracellular proteins (phospho-specific STATs, total
STAT levels, SOCS1, and BCL3) the BD Phosflow Alternative
Protocol 1 was used and slightly modified. Generally, spleen
leukocytes were isolated, stimulated (where appropriate), fixed,
stained for surface molecules, permeabilized, and finally stained
for intracellular proteins. Spleens were isolated, and single cell
suspensions were prepared. Red blood cells were lysed by addition
of 0.84% NH4Cl solution, and cells were plated at 2–4610
6 cells
per well in 96 well round bottom plates. Cells were incubated at
37uC in 100 ml of media (RPMI supplemented with 10% FCS and
pen-strep and L-Glut) for the indicated times in the presence
(stimulated) or absence (unstimulated) of cytokines. Total volume
was brought up to 200 ml before spinning. Cells were fixed with
BD cytofix (BD Bioscience) on ice for 20 min, washed with Flow
Cytometry Buffer and blocked with a-FcR (2.4G2) for 5 min at
4uC. Cells were washed and stained with a variety of fluorescently
labeled MAbs for 20 min at 4uC, washed with Flow Cytometry
Buffer, and then permeablized with BD Perm buffer III (BD
Bioscience) for 30 min on ice. Splenocytes were washed and then
stained with a combination of fluorescently labeled Abs pY701
STAT1 (BD Bioscience), pY705 STAT3 (BD Bioscience), pY693
STAT4 (BD Bioscience), pY694 STAT5 (BD Bioscience), STAT1
(clone 1/Stat1; BD Bioscience), or unlabeled Abs STAT3 (79D7;
cell signaling technology), STAT4 (C46B10; cell signaling
technology), STAT5 (3H7; cell signaling technology), SOCS1
(A156; cell signaling technology), or BCL3 (C-14; Santa Cruz
Biotechnology) for 20–30 min at RT in the dark. If antibodies
were not fluorescently labeled, cells were washed and then stained
with FITC-labeled donkey anti-Rabbit IgG (Poly4064; BioLegend)
for 15 min at RT in the dark. After intracellular staining,
splenocytes were washed and samples were acquired using a BD
Bioscience LSR II flow cytometry with FACS Diva software. Data
were analyzed with FlowJo software.
RNA isolation and quantitative real time PCR
Naı¨ve CD44lo CD8 T cells were sorted to 98–99% purity using
MACS Naı¨ve CD8a+ T cell Isolation Kit (Miltenyi Biotec). RNA
was isolated from sorted naı¨ve CD8 T cells with an RNeasy mini
kit (Qiagen) and concentration was determined. cDNA was
generated using the RT2 Easy First Strand Kit (Qiagen) and
QuantiFast SYBR Green PCR Kit (Qiagen) was used to
determine the relative mRNA concentrations by quantitative
real-time PCR. Primers for Socs1 (RefSeq Accession number
NM_009896.2) and Actb (RefSeq Accession number
NM_007393.3) were used.
Trogocytosis assay
When CD8 T cells kill target cells, they strip off part of the
target cell membrane and incorporate it into their own, by a
process called trogocytosis [53,54]. A trogocytosis assay was thus
performed to measure the ability of P14 T cells to attack targets.
Effector P14 cells were generated as described in earlier materials
and methods sections. Briefly, P14 mice were either HBSS or
poly(I:C) treated for 1 day prior to adoptive transfer ,10,000 total
P14 cells per group into separate animals subsequently infected
with LCMV. Spleens were harvested at day 5 post infection and
single cell suspensions were obtained. Targets were RMA cells
cultured in complete RPMI and were un-pulsed, pulsed with an
irrelevant peptide, K3L (YSLPNAGDVI) or pulsed with a specific
peptide, GP33 (KAVYNFATC), at 1 mM for ,90–120 minutes at
37uC. After incubation, target cells were labeled with fluorescent
lipids SP-DiIC18(3) (Molecular probes) and diluted in Diluent C
(Sigma Aldrich) using the protocol adapted from Daubeuf S. et al
[54]. Target cells (,76105) were co-cultured with effector cells
(1.56106 total splenocytes) per well for 1 hour at 37uC. Cells were
stained with surface antibodies of interest, and samples were
acquired using a BD Bioscience LSR II flow cytometry with FACS
Diva software. Data were analyzed with FlowJo software.
Statistical analyses
Where appropriate, Students t test and linear regression were
calculated using GraphPad InStat software. Significance was set at
a P value of 0.05; * indicates a P of,0.05, ** a P of,0.01, *** a P
of ,0.001, and **** a P of ,0.0001. All results are expressed as
means of +/2 standard deviations.
Supporting Information
Figure S1 Poly(I:C)-pretreated memory phenotype CD8
T cells are refractory to IFNb-induced STAT phosphor-
ylation. As described in Figure 2 and Materials and Methods,
mice were HBSS (open bars) or poly(I:C) (black bars) treated for 1
day. Splenocytes were isolated and were either unstimulated, or
stimulated ex vivo with IFNb for 30 min and then stained for (A)
pSTAT1, (B) pSTAT3, (C), pSTAT4, and (D) pSTAT5. Cells
were gated on CD44hi CD8a+ lymphocytes, and the MFI of each
respective pSTAT is graphed. Data are representative of at least 4
independent experiments with n of 3 mice per group. Statistical
analysis is described in Materials and Methods section.
(EPS)
Figure S2 Naı¨ve CD44lo CD8 T cells do not phosphor-
ylate downstream STATs in response to other cytokines.
As described in Figure 4 and Materials and Methods, mice were
HBSS (open bars) or poly(I:C) (black bars) treated for 1 day.
Splenocytes were isolated and were unstimulated, stimulated with
IFNb, IL-2, IL-7, or IL-12 for 30 min and stained for appropriate
downstream STAT molecules (A–B) pSTAT5 MFI, and (C)
pSTAT4 MFI. Splenocytes were gated on CD44lo CD8a+
lymphocytes. (A) responsiveness to IFNb and IL-2, (B) responsive-
ness to IFNb and IL-7, and (C) responsiveness to IFNb and IL-12.
Data are representative of at least 2 independent experiments with
n of 3 mice per group.
(EPS)
Figure S3 CD44hi CD8 T cells respond to some
cytokines after 1 day of poly(I:C) treatment. As described
in Figure 4, mice were inoculated with HBSS(open bars) or
poly(I:C) (black bars) for 1 day. Splenocytes were isolated and
either unstimulated or stimulated with IL-6 (A), or IL-15 (B) and
stained for downstream pSTAT3 (A) or pSTAT5 (B). Splenocytes
were gated on CD44hi CD8a+ lymphocytes and plotted for
pSTAT MFI. Data are representative of at least 2 independent
experiments with n of 3 mice per group.
(EPS)
Figure S4 Cytokine receptor expression after 1, 2, or 3
days of poly(I:C)-pretreatment. As described in Figure 5,
mice were given one dose of HBSS (open bars) or poly(I:C) (black
bars) and harvested at 1, 2, or 3 days after the inoculation.
Cytokine receptor expression was determined on the CD44lo
CD8a+ T cells. The MFI is plotted for (A) CD25, (B) CD122, (C)
CD126, (D) CD127, and (E) CD132. Cytokine receptors tested
include IL-2 (A–B, E), IL-6 (C), IL-7 (D–E) and IL-15 (B, E). Data
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are representative of 2 independent experiments with n of 3 mice
per group.
(EPS)
Figure S5 Memory phenotype CD8 T cells increase
SOCS1 expression after poly(I:C) treatment. As described
in Figure 5, mice were given one dose of HBSS (open bars) or
poly(I:C) (black bars) and harvested at 1, 2, or 3 days after the
inoculation. Splenocytes were gated on CD44hi CD8a+ T cells
showing MFI of (A) IFNAR1 and (B) SOCS1. Data are
representative of 2 independent experiments with n of 3 mice
per group.
(EPS)
Figure S6 Trogocytosis capability of HBSS- and
poly(I:C)-pretreated P14 cells co-cultured with GP33
pulsed RMA cells. As described in the Materials and Methods
section, a trogocytosis assay was performed using day 5 HBSS- or
poly(I:C)-pretreated P14 CD8 T cells as effectors and RMA cells
pulsed with peptides as targets. Effectors were developed by
poly(I:C) or HBSS treating a P14 transgenic mouse, transferring
,10,000 P14 cells from each group into separate mice 1 day after
treatment and infecting the recipient mice with LCMV. At day 5
post infection, splenocytes containing the donor P14 CD8 T cells
were isolated and used as effectors. Target cells were RMA cells
that were not pulsed with peptide (no peptide), pulsed with an
irrelevant peptide (K3L), or pulsed with the specific peptide
(GP33). Target cells were labeled with fluorescent lipid molecule
SP-DiIC18(3) that can be detected if it is transferred to a different
cell through trogocytosis. Target cells were in excess and were co-
incubated with effectors for 1 hour, stained with surface antibodies
and ran on a flow cytometer. (A) shows representative FACS plots
gated on donor P14 cells that were HBSS or poly(I:C) pretreated
co-incubated with 1. No targets, 2. No peptide pulsed targets, 3.
K3L pulsed targets, or 4. GP33 pulsed targets, looking at P14 cell
incorporation of SP-DiIC18(3). Data are representative of 2
independent experiments with n of 3–5 mice per group. (B) MFI
of SP-DiIC18(3) gated on donor P14 cells, normalized to HBSS
control for K3L and GP33 pulsed targets. HBSS pretreated P14
cells are in the open bars and poly(I:C)-pretreated P14 cells
represented as black bars. Data are combined from 2 independent
experiments with a total n of 8 mice per group.
(EPS)
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